As more research studies incorporate next-generation sequencing (including whole-genome or whole-exome sequencing), investigators and institutional review boards face difficult questions regarding which genomic results to return to research participants and how. An American College of Medical Genetics and Genomics 2013 policy paper suggesting that pathogenic mutations in 56 specified genes should be returned in the clinical setting has raised the question of whether comparable recommendations should be considered in research settings. The Clinical Sequencing Exploratory Research (CSER) Consortium and the Electronic Medical Records and Genomics (eMERGE) Network are multisite research programs that aim to develop practical strategies for addressing questions concerning the return of results in genomic research. CSER and eMERGE committees have identified areas of consensus regarding the return of genomic results to research participants. In most circumstances, if results meet an actionability threshold for return and the research participant has consented to return, genomic results, along with referral for appropriate clinical follow-up, should be offered to participants. However, participants have a right to decline the receipt of genomic results, even when doing so might be viewed as a threat to the participants' health. Research investigators should be prepared to return research results and incidental findings discovered in the course of their research and meeting an actionability threshold, but they have no ethical obligation to actively search for such results. These positions are consistent with the recognition that clinical research is distinct from medical care in both its aims and its guiding moral principles.
Copyright © 2014 The American Society of Human Genetics. Published by Elsevier Inc. All rights reserved.
Can I be sued for that? Liability risk and the disclosure of clinically significant genetic research findings.Genome Res. 2014 May;24(5):719-23. doi: 10.1101/gr.170514.113. Epub 2014 Mar 27. Genome Res. 2014. PMID: 24676095 Free PMC article.
Models of consent to return of incidental findings in genomic research.Hastings Cent Rep. 2014 Jul-Aug;44(4):22-32. doi: 10.1002/hast.328. Epub 2014 Jun 11. Hastings Cent Rep. 2014. PMID: 24919982 Free PMC article.
Processes and preliminary outputs for identification of actionable genes as incidental findings in genomic sequence data in the Clinical Sequencing Exploratory Research Consortium.Genet Med. 2013 Nov;15(11):860-7. doi: 10.1038/gim.2013.133. Epub 2013 Oct 24. Genet Med. 2013. PMID: 24195999 Free PMC article. Review.
The legal risks of returning results of genomics research.Genet Med. 2012 Apr;14(4):473-7. doi: 10.1038/gim.2012.10. Epub 2012 Feb 9. Genet Med. 2012. PMID: 22323070 Free PMC article.
Return of individual research results and incidental findings: facing the challenges of translational science.Annu Rev Genomics Hum Genet. 2013;14:557-77. doi: 10.1146/annurev-genom-091212-153506. Epub 2013 Jul 15. Annu Rev Genomics Hum Genet. 2013. PMID: 23875796 Free PMC article. Review.
Cited by 155 articles
Pioneering Informed Consent for Return of Research Results to Breast Cancer Patients Facing Barriers to Implementation of Genomic Medicine: The Kenyan BRCA1/2 Testing Experience Using Whole Exome Sequencing.Front Genet. 2020 Mar 6;11:170. doi: 10.3389/fgene.2020.00170. eCollection 2020. Front Genet. 2020. PMID: 32231682 Free PMC article.
What Results Should Be Returned from Opportunistic Screening in Translational Research?J Pers Med. 2020 Mar 1;10(1):13. doi: 10.3390/jpm10010013. J Pers Med. 2020. PMID: 32121581 Free PMC article.
Returning Individual Genetic Research Results to Research Participants: Uptake and Outcomes Among Patients With Breast Cancer.JCO Precis Oncol. 2018;2:10.1200/po.17.00250. doi: 10.1200/po.17.00250. Epub 2018 Apr 16. JCO Precis Oncol. 2018. PMID: 32095738 Free PMC article.
Pathogenic and Uncertain Genetic Variants Have Clinical Cardiac Correlates in Diverse Biobank Participants.J Am Heart Assoc. 2020 Feb 4;9(3):e013808. doi: 10.1161/JAHA.119.013808. Epub 2020 Feb 3. J Am Heart Assoc. 2020. PMID: 32009526 Free PMC article.
Why genomics researchers are sometimes morally required to hunt for secondary findings.BMC Med Ethics. 2020 Jan 31;21(1):11. doi: 10.1186/s12910-020-0449-8. BMC Med Ethics. 2020. PMID: 32005225 Free PMC article.
- U01HG006379/HG/NHGRI NIH HHS/United States
- U01 HG006375/HG/NHGRI NIH HHS/United States
- U01HG006375/HG/NHGRI NIH HHS/United States
- R01 HG004500/HG/NHGRI NIH HHS/United States
- U01 HG007301/HG/NHGRI NIH HHS/United States
- 1R01CA154517/CA/NCI NIH HHS/United States
- U01 HG006382/HG/NHGRI NIH HHS/United States
- U01HG006382/HG/NHGRI NIH HHS/United States
- U01 HG004603/HG/NHGRI NIH HHS/United States
- R01 HG006615/HG/NHGRI NIH HHS/United States
- U01HG04603/HG/NHGRI NIH HHS/United States
- U01 HG006507/HG/NHGRI NIH HHS/United States
- R21HG00612/HG/NHGRI NIH HHS/United States
- U01HG007307/HG/NHGRI NIH HHS/United States
- U01HG006500/HG/NHGRI NIH HHS/United States
- U01 HG006828/HG/NHGRI NIH HHS/United States
- U01 HG007278/HG/NHGRI NIH HHS/United States
- U01HG006507/HG/NHGRI NIH HHS/United States
- U01 HG006380/HG/NHGRI NIH HHS/United States
- R01 CA154517/CA/NCI NIH HHS/United States
- U01 HG006500/HG/NHGRI NIH HHS/United States
- U01 G006492/PHS HHS/United States
- UL1 TR000067/TR/NCATS NIH HHS/United States
- UL1 TR001425/TR/NCATS NIH HHS/United States
- U01 HG006378/HG/NHGRI NIH HHS/United States
- UL1 TR000077/TR/NCATS NIH HHS/United States
- U01 HG006379/HG/NHGRI NIH HHS/United States
- U01HG006378/HG/NHGRI NIH HHS/United States
- UM1 HG007301/HG/NHGRI NIH HHS/United States
- U01 HG007307/HG/NHGRI NIH HHS/United States
- U01 HG006487/HG/NHGRI NIH HHS/United States
- U01HG006828/HG/NHGRI NIH HHS/United States
- U01 HG006492/HG/NHGRI NIH HHS/United States